Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares (2020 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Preferred Shares of $61.2 million for Q1 2026, down 52.08% year-over-year from $127.7 million in Q1 2025, and down 13.66% quarter-over-quarter from $70.9 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares (2020 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Preferred Shares history runs 7 years deep, the most recent figure standing at $61.2 million for Q1 2026.
- In Q1 2026, Preferred Shares fell 52.08% year-over-year to $61.2 million; the TTM figure through Mar 2026 stood at $61.2 million (down 52.08% YoY), while the FY2025 annual figure was $70.9 million, up 15.82% from the prior year.
- Preferred Shares for Q1 2026 stood at $61.2 million, down from $70.9 million in the prior quarter.
- The five-year high for Preferred Shares was $128.3 million in Q4 2023, with the low at $15.7 million in Q2 2022.
- The 5-year median for Preferred Shares is $78.2 million (2023), against an average of $84.1 million.
- The sharpest annual moves came in 2023 and 2024: Preferred Shares soared 399.3% in 2023, then slumped 52.3% in 2024.
- Viridian Therapeutics, Inc.\DE's Preferred Shares stood at $85.5 million in 2022, then jumped by 50.09% to $128.3 million in 2023, then plunged by 52.3% to $61.2 million in 2024, then gained by 15.82% to $70.9 million in 2025, then slipped by 13.66% to $61.2 million in 2026.
- Business Quant data shows VRDN's Preferred Shares at $61.2 million in Q1 2026, $70.9 million in Q4 2025, and $61.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 60.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.43 Mn |
| Mar 31, 2026 | 61.19 Mn |
| Dec 31, 2025 | 70.87 Mn |
| Sep 30, 2025 | 61.19 Mn |
| Jun 30, 2025 | 61.19 Mn |
| Mar 31, 2025 | 127.70 Mn |
| Dec 31, 2024 | 61.19 Mn |
| Sep 30, 2024 | 127.70 Mn |
| Jun 30, 2024 | 128.28 Mn |
| Mar 31, 2024 | 128.28 Mn |
| Dec 31, 2023 | 128.28 Mn |
| Sep 30, 2023 | 56.68 Mn |
| Jun 30, 2023 | 78.24 Mn |
| Mar 31, 2023 | 56.68 Mn |
| Dec 31, 2022 | 85.47 Mn |
| Sep 30, 2022 | 85.47 Mn |
| Jun 30, 2022 | 15.67 Mn |
| Mar 31, 2022 | 96.44 Mn |
| Dec 31, 2021 | 118.16 Mn |
| Sep 30, 2021 | 145.79 Mn |